Getagraph.com logo
S&P 500
(0.32%) 5 116.17 points
Dow Jones
(0.38%) 38 386 points
Nasdaq
(0.35%) 15 983 points
Oil
(-1.35%) $82.72
Gas
(6.34%) $2.05
Gold
(0.06%) $2 348.50
Silver
(-0.30%) $27.45
Platinum
(4.12%) $960.05
USD/EUR
(-0.21%) $0.933
USD/NOK
(-0.37%) $10.98
USD/GBP
(-0.54%) $0.796
USD/RUB
(1.66%) $93.40

Echtzeitaktualisierungen für Supernus Pharmaceuticals [SUPN]

Börse: NASDAQ Sektor: Healthcare Industrie: Drug Manufacturers—Specialty & Generic
BUY
66.67%
return 2.21%
SELL
33.33%
return 3.32%
Zuletzt aktualisiert29 Apr 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

1.76% $ 30.60

VERKAUFEN 108381 min ago

@ $27.40

Ausgestellt: 14 Feb 2024 @ 15:30

Rendite: 11.68%

Vorheriges Signal: Feb 13 - 15:30

Vorheriges Signal: Kaufen

Rendite: -0.36 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States...

Stats
Tagesvolumen 313 257
Durchschnittsvolumen 389 188
Marktkapitalisierung 1.67B
EPS $0 ( 2024-02-27 )
Nächstes Ertragsdatum ( $0.390 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 1 530.00
ATR14 $0.0460 (0.15%)
Insider Trading
Date Person Action Amount type
2024-03-21 Bhatt Padmanabh P. Buy 14 491 Common Stock
2024-03-21 Bhatt Padmanabh P. Sell 14 491 Employee Stock Option (Right to Buy)
2024-03-21 Bhatt Padmanabh P. Sell 14 491 Common Stock
2024-03-20 Bhatt Padmanabh P. Sell 400 Employee Stock Option (Right to Buy)
2024-03-20 Bhatt Padmanabh P. Buy 400 Common Stock
INSIDER POWER
38.23
Last 100 transactions
Buy: 802 366 | Sell: 356 762

Volumen Korrelation

Lang: -0.12 (neutral)
Kurz: 0.06 (neutral)
Signal:(37.209) Neutral

Supernus Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
FGEN0.881
CRNC0.878
IPHA0.878
CRTO0.876
ORIC0.875
TBNK0.873
MOMO0.87
VRDN0.869
RGLD0.868
DOOO0.868
10 Am meisten negativ korreliert
PCRX-0.866
LLNW-0.859
SFET-0.848
NBRV-0.842
MTEX-0.834
IMTX-0.831
ZENV-0.831
SWAV-0.829
DSPC-0.827
RIVN-0.825

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Supernus Pharmaceuticals Korrelation - Währung/Rohstoff

The country flag -0.61
( weak negative )
The country flag -0.52
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.36
( neutral )
The country flag 0.37
( neutral )
The country flag -0.37
( neutral )

Supernus Pharmaceuticals Finanzdaten

Annual 2023
Umsatz: $607.52M
Bruttogewinn: $438.88M (72.24 %)
EPS: $0.0241
FY 2023
Umsatz: $607.52M
Bruttogewinn: $438.88M (72.24 %)
EPS: $0.0241
FY 2022
Umsatz: $667.24M
Bruttogewinn: $580.02M (86.93 %)
EPS: $1.130
FY 2021
Umsatz: $579.78M
Bruttogewinn: $504.71M (87.05 %)
EPS: $1.010

Financial Reports:

No articles found.

Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.